705 related articles for article (PubMed ID: 8301131)
1. Stimulation of tumor-draining lymph node cells with superantigenic staphylococcal toxins leads to the generation of tumor-specific effector T cells.
Shu S; Krinock RA; Matsumura T; Sussman JJ; Fox BA; Chang AE; Terman DS
J Immunol; 1994 Feb; 152(3):1277-88. PubMed ID: 8301131
[TBL] [Abstract][Full Text] [Related]
2. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2.
Yoshizawa H; Chang AE; Shu S
J Immunol; 1991 Jul; 147(2):729-37. PubMed ID: 1830072
[TBL] [Abstract][Full Text] [Related]
3. Cellular interactions in effector cell generation and tumor regression mediated by anti-CD3/interleukin 2-activated tumor-draining lymph node cells.
Yoshizawa H; Chang AE; Shu SY
Cancer Res; 1992 Mar; 52(5):1129-36. PubMed ID: 1531321
[TBL] [Abstract][Full Text] [Related]
4. Treatment of intracranial tumors by systemic transfer of superantigen-activated tumor-draining lymph node T cells.
Inoue M; Plautz GE; Shu S
Cancer Res; 1996 Oct; 56(20):4702-8. PubMed ID: 8840987
[TBL] [Abstract][Full Text] [Related]
5. Characteristics and in vivo homing of long-term T-cell lines and clones derived from tumor-draining lymph nodes.
Matsumura T; Sussman JJ; Krinock RA; Chang AE; Shu S
Cancer Res; 1994 May; 54(10):2744-50. PubMed ID: 8168105
[TBL] [Abstract][Full Text] [Related]
6. Cross-reactivity of anti-CD3/IL-2 activated effector cells derived from lymph nodes draining heterologous clones of a murine tumor.
Matsumura T; Krinock RA; Chang AE; Shu S
Cancer Res; 1993 Sep; 53(18):4315-21. PubMed ID: 8364926
[TBL] [Abstract][Full Text] [Related]
7. Adoptive immunotherapy with tumor-specific T lymphocytes generated from cytokine gene-modified tumor-primed lymph node cells.
Ohno K; Yoshizawa H; Tsukada H; Takeda T; Yamaguchi Y; Ichikawa K; Maruyama Y; Suzuki Y; Suzuki E; Arakawa M
J Immunol; 1996 May; 156(10):3875-81. PubMed ID: 8621926
[TBL] [Abstract][Full Text] [Related]
8. Differential effects of superantigen-induced "anergy" on priming and effector stages of a T cell-dependent antibody response.
Lussow AR; MacDonald HR
Eur J Immunol; 1994 Feb; 24(2):445-9. PubMed ID: 8299694
[TBL] [Abstract][Full Text] [Related]
9. Augmentation of antitumor immunity with bacterial superantigen, staphylococcal enterotoxin B-bound tumor cells.
Shimizu M; Yamamoto A; Nakano H; Matsuzawa A
Cancer Res; 1996 Aug; 56(16):3731-6. PubMed ID: 8706016
[TBL] [Abstract][Full Text] [Related]
10. Acquired resistance to superantigen-induced T cell shock. V beta selective T cell unresponsiveness unfolds directly from a transient state of hyperreactivity.
Miethke T; Wahl C; Heeg K; Wagner H
J Immunol; 1993 May; 150(9):3776-84. PubMed ID: 8473732
[TBL] [Abstract][Full Text] [Related]
11. Cellular basis of immunologic interactions in adoptive T cell therapy of established metastases from a syngeneic murine sarcoma.
Ward BA; Shu S; Chou T; Perry-Lalley D; Chang AE
J Immunol; 1988 Aug; 141(3):1047-53. PubMed ID: 3260908
[TBL] [Abstract][Full Text] [Related]
12. Phenotype analyses and cellular mechanisms of the pre-effector T-lymphocyte response to a progressive syngeneic murine sarcoma.
Sakai K; Chang AE; Shu SY
Cancer Res; 1990 Jul; 50(14):4371-6. PubMed ID: 2114215
[TBL] [Abstract][Full Text] [Related]
13. Implantation of IL-2-containing osmotic pump prolongs the survival of superantigen-reactive T cells expanded in mice injected with bacterial superantigen.
Kuroda K; Yagi J; Imanishi K; Yan XJ; Li XY; Fujimaki W; Kato H; Miyoshi-Akiyama T; Kumazawa Y; Abe H; Uchiyama T
J Immunol; 1996 Aug; 157(4):1422-31. PubMed ID: 8759722
[TBL] [Abstract][Full Text] [Related]
14. T cells made deficient in interleukin-2 production by exposure to staphylococcal enterotoxin B in vivo are primed for interferon-gamma and interleukin-10 secretion.
Florquin S; Amraoui Z; Goldman M
Eur J Immunol; 1995 May; 25(5):1148-53. PubMed ID: 7774618
[TBL] [Abstract][Full Text] [Related]
15. Immunopharmacology of the superantigen staphylococcal enterotoxin A in T-cell receptor V beta 3 transgenic mice.
Dohlsten M; Björklund M; Sundstedt A; Hedlund G; Samson D; Kalland T
Immunology; 1993 Aug; 79(4):520-7. PubMed ID: 7691731
[TBL] [Abstract][Full Text] [Related]
16. Purification of L-selectin(low) cells promotes the generation of highly potent CD4 antitumor effector T lymphocytes.
Kagamu H; Shu S
J Immunol; 1998 Apr; 160(7):3444-52. PubMed ID: 9531305
[TBL] [Abstract][Full Text] [Related]
17. Type 1 versus type 2 cytokine release by Vbeta T cell subpopulations determines in vivo antitumor reactivity: IL-10 mediates a suppressive role.
Aruga A; Aruga E; Tanigawa K; Bishop DK; Sondak VK; Chang AE
J Immunol; 1997 Jul; 159(2):664-73. PubMed ID: 9218581
[TBL] [Abstract][Full Text] [Related]
18. Study of activation of murine T cells with bacterial superantigens. In vitro induction of enhanced responses in CD4+ T cells and of anergy in CD8+ T cells.
Yan XJ; Li XY; Imanishi K; Kumazawa Y; Uchiyama T
J Immunol; 1993 May; 150(9):3873-81. PubMed ID: 8097227
[TBL] [Abstract][Full Text] [Related]
19. In vivo tumor immunotherapy by a bacterial superantigen.
Ochi A; Migita K; Xu J; Siminovitch K
J Immunol; 1993 Sep; 151(6):3180-6. PubMed ID: 8376773
[TBL] [Abstract][Full Text] [Related]
20. In vivo antitumor efficacy of tumor-draining lymph node cells activated with nonspecific T-cell reagents.
Shu S; Sussman JJ; Chang AE
J Immunother Emphasis Tumor Immunol; 1993 Nov; 14(4):279-85. PubMed ID: 8280709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
